On September 22, 2025, Mira Pharmaceuticals announced positive results from a Phase 1 study of its oral drug Ketamir-2, showing it was safe and well-tolerated at doses between 50 mg and 600 mg, with no severe adverse effects reported. The company will now proceed with the next phase of trials.